New study aims to understand heart recovery after immunotherapy
NCT ID NCT07278817
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 340 patients who developed heart injury from immune checkpoint inhibitors, a type of cancer immunotherapy. Researchers will track their recovery using both traditional Chinese and Western medicine approaches. The goal is to better understand the disease and improve rehabilitation programs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better understand how to monitor and support recovery in patients with this rare but serious heart condition.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. It may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 340 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Under the established protocol, patients presenting with ICIACI will be enrolled from the China-Japan Friendship Hospital, Fuwai Hospital of the Chinese Academy of Medical Sciences, the Second Affiliated Hospital of Nanchang University, and Weifang Hospital of Traditional Chinese Medicine during the period from December 2025 to July 2028.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18 to 80 years, inclusive * Malignancy confirmed by cytology or histopathology * Diagnosis of ICIACI following ICI therapy * Assessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation. Exclusion Criteria: * Diagnosis of fulminant myocarditis or cardiac function of NYHA IV * Clear evidence suggesting cardiac injury not attributable to ICIs * Concurrent acute cardiovascular events or malignant arrhythmias * Coexisting severe immune-related adverse events affecting other organ systems * Associated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Immune checkpoint inhibitor-related myocarditis are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.